Marksans Pharma gets inspection report for New York unit

PTI New Delhi | Updated on February 11, 2020

Marksans Pharma on Tuesday said it has received an establishment inspection report (EIR) from the US health regulator for company’s manufacturing facility in the US.

In a regulatory filing, the company announced “receipt of the EIR from US Food and Drug Administration (USFDA) in respect of inspection of company’s manufacturing facility Time-Cap Laboratories Inc. located at Farmingdale, New York, USA carried out from December 5 to December 18, 2019“.

The shares of the company were trading at ₹23.20 apiece on BSE, up 4.98 per cent from the previous close.

Published on February 11, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like